Will All US Biosimilar mAbs Be Interchangeable In The Long Run?
Landmark Adalimumab Approval Sparks Debate For Controversial Designation
Executive Summary
As Boehringer Ingelheim’s Cyltezo has become the second-ever interchangeable biosimilar approved by the US FDA – as well as the first monoclonal antibody to garner the designation and offering the first published data from a switching trial to support interchangeability – the debate around the potential impact for interchangeable products in the keenly-watched adalimumab space and beyond continues to grow.
You may also be interested in...
Samsung Bioepis ‘Setting A High Bar’ For Next Wave Of Biosimilars
In the wake of parent company Samsung Biologics completing its full acquisition of Samsung Bioepis, the Korea-based biosimilars player has told Generics Bulletin that it will be a “more robust company,” as it applies more rigorous standards to replenishing its pipeline of biosimilar candidates.
Humira One Year Out: The Largest LOE Event In US Pharma History
Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.
Humira One Year Out: The Largest LOE Event In US Pharma History
Ahead of the first biosimilar Humira product set to launch in 365 days, Generics Bulletin provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.